Journal of Surgery Concepts & Practice ›› 2021, Vol. 26 ›› Issue (06): 543-549.doi: 10.16139/j.1007-9610.2021.06.017
• Original article • Previous Articles Next Articles
LIU Shiguang, ZHAO Jingkun, LU Aiguo, MAO Zhihai()
Received:
2020-05-09
Online:
2021-11-25
Published:
2022-07-27
Contact:
MAO Zhihai
E-mail:zhihaimao@163.com
CLC Number:
LIU Shiguang, ZHAO Jingkun, LU Aiguo, MAO Zhihai. Expression of chemokine CXCL5 and programme death ligand 1 in colorectal cancer tissues are associated with prognosis of patients[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 543-549.
临床特征 | CXCL5表达 | 统计学数值 | P值 | PD-L1表达 | 统计学数值 | P值 | ||
---|---|---|---|---|---|---|---|---|
高 | 低 | 高 | 低 | |||||
总计 | 48 | 30 | 37 | 41 | ||||
性别 | 1.086 | 0.297 | 1.236 | 0.266 | ||||
男 | 23 | 18 | 17 | 24 | ||||
女 | 25 | 12 | 20 | 17 | ||||
年龄(岁) | 0.194 | 0.660 | 0.360 | 0.549 | ||||
<65 | 28 | 19 | 21 | 26 | ||||
≥65 | 20 | 11 | 16 | 15 | ||||
组织学 | 3.534 | 0.171 | 2.982 | 0.225 | ||||
管状 | 38 | 28 | 29 | 37 | ||||
黏液 | 9 | 2 | 7 | 4 | ||||
乳头状 | 1 | 0 | 1 | 0 | ||||
肿瘤直径(cm) | 3.945 | 0.047 | 4.029 | 0.045 | ||||
≥5 | 27 | 10 | 22 | 15 | ||||
<5 | 21 | 20 | 15 | 26 | ||||
TNM分期 | 2.735 | 0.003 | 11.733 | 0.008 | ||||
Ⅰ | 5 | 10 | 4 | 10 | ||||
Ⅱ | 21 | 12 | 11 | 16 | ||||
Ⅲ | 16 | 8 | 16 | 15 | ||||
Ⅳ | 6 | 0 | 6 | 0 |
参数 | 总生存率 | ||
---|---|---|---|
HR | 95% CI | P值 | |
单因素分析 | |||
年龄(岁)(<65比≥65) | 1.003 | 0.410~2.454 | 0.995 |
性别(女比男) | 1.812 | 0.740~4.433 | 0.193 |
组织学 | |||
乳头状 | 1.000 | .. | 0.222 |
管状比乳头状 | 0.164 | 0.021~1.272 | 0.084 |
黏液比乳头状 | 0.198 | 0.020~1.948 | 0.165 |
TNM分期 | |||
Ⅲ+Ⅳ比Ⅰ+Ⅱ | 0.181 | 0.060~0.541 | 0.002 |
肿瘤直径(<5 cm比≥5 cm) | 0.537 | 0.219~1.314 | 0.173 |
CXCL5(低表达比高表达) | 0.229 | 0.067~0.783 | 0.019 |
PD-L1(低表达比高表达) | 0.397 | 0.164~0.958 | 0.040 |
多因素分析 | |||
TNM分期 | |||
Ⅲ+Ⅳ比Ⅰ+Ⅱ | 0.235 | 0.075~0.734 | 0.013 |
CXCL5(低表达比高表达) | 0.786 | 0.202~3.063 | 0.728 |
PD-L1(低表达比高表达) | 0.156 | 0.042~0.584 | 0.006 |
TNM分期 | |||
Ⅲ+Ⅳ比Ⅰ+Ⅱ | 0.234 | 0.076~0.721 | 0.011 |
CXCL5(低表达比高表达) | 0.345 | 0.098~1.215 | 0.098 |
[1] | Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2):74-108. |
[2] | 陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2018, 27(1):1-14. |
[3] | Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy[J]. Immunity, 2020, 52(1):17-35. |
[4] | Borsig L, Wolf MJ, Roblek M, et al. Inflammatory chemokines and metastasis-tracing the accessory[J]. Oncogene, 2014, 33(25):3217-3224. |
[5] | Stillie R, Farooq SM, Gordon JR, et al. The functional significance behind expressing two IL-8 receptor types on PMN[J]. J Leukoc Biol, 2009, 86(3):529-543. |
[6] | Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial- neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer[J]. J Clin Invest, 1998, 102(3):465-472. |
[7] | Begley LA, Kasina S, Mehra R, et al. CXCL 5 promotes prostate cancer progression[J]. Neoplasia, 2008, 10(3):244-254. |
[8] | Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma[J]. Leukemia, 2014, 28(5):993-1000. |
[9] | Zhao J, Ou B, Han D, et al. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways[J]. Mol Cancer, 2017, 16(1):70. |
[10] | Hsu YL, Hou MF, Kuo PL, et al. Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway[J]. Oncogene, 2013, 32(37):4436-4447. |
[11] | Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling[J]. Oncogene, 2016, 35(20):2634-2644. |
[12] | Chang MS, Mcninch J, Basu R, et al. Cloning and cha-racterization of the human neutrophil-activating peptide (ENA-78) gene[J]. J Biol Chem, 1994, 269(41):25277-25282. |
[13] | Walz A, Burgener R, Car B, et al. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8[J]. J Exp Med, 1991, 174(6):1355-1362. |
[14] | Z′Graggen K, Walz A, Mazzucchelli L, et al. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease[J]. Gastroenterology, 1997, 113(3):808-816. |
[15] | Lu B, Chen L, Liu L, et al. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract[J]. Immunol Res, 2011, 50(2-3):269-275. |
[16] | Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death ligand-1 is a prognostic factor for malignant melanoma[J]. Cancer, 2010, 116(7):1757-1766. |
[17] | Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer[J]. Exp Mol Pathol, 2014, 96(3):284-291. |
[18] | Qin T, Zeng YD, Qin G, et al. High PD-L 1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer[J]. Oncotarget, 2015, 6(32):33972-33981. |
[19] | Shi SJ, Wang LJ, Wang GD, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells[J]. PLoS One, 2013, 8(10):e76012. |
[20] | Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer[J]. Eur J Cancer, 2013, 49(9):2233-2242. |
[21] | Li Z, Zhou J, Zhang J, et al. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5[J]. Int J Cancer, 2019, 145(7):1946-1957. |
[22] | Wang Y, Zhuang Q, Zhou S, et al. Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance[J]. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(1):77-79. |
[23] | Speetjens FM, Kuppen PJ, Sandel MH, et al. Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients[J]. Clin Cancer Res, 2008, 14(8):2276-2284. |
[24] | 李芮. 综合护理干预对烧伤患者趋势因子及创面愈合的影响[J]. 实用临床护理学杂志, 2017, 2(45):56-59. |
[25] | 焦海良, 朱斌, 苏瑞洋. 多学科协作诊治模式下结直肠癌术前辅助检查系统的临床应用初步探索[J]. 当代医学, 2017, 23(22):42-44. |
[1] | ZHAO Hui (赵晖),WEN Baiqing (文柏清),KANG Yani*(康亚妮). Gene Expression Profiling Identifies Potential Biomarkers for Colorectal Cancer Using NanoString nCounter Assay [J]. J Shanghai Jiaotong Univ Sci, 2023, 28(4): 432-. |
[2] | WANG Han, LU Haidi, WANG Lei, CONG Wenming, ZHENG Jianming, BAI Chenguang. Clinicopathological features of 2 cases of squamous cell carcinoma and 2 cases of adenosquamous carcinoma [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 44-49. |
[3] | LI Jiaxi, WANG Jinjiang, YU Liping, YUAN Ying, QIAO Guanglei, MA Lijun. Effect of RAB25 knockdown on ferroptosis of colorectal cancer cells [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(06): 710-718. |
[4] | YANG Ruixin, DU Yutong, YAN Ranlin, ZHU Zhenggang, LI Chen, YU Yingyan. Improving exploration of biological sample pretreatment in single-cell transcriptome sequencing of gastrointestinal tumors [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 567-574. |
[5] | ZHANG Hua, LU Wei, YANG Chengyi, XIANG Mingjie. Value of serum FBLN1 detection in diagnosis and prognosis prediction of colorectal cancer [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 462-465. |
[6] | WANG Changgang, LIU Kun, FENG Haoran, JIANG Yimei, SHI Yiqing, CHEN Xianze, SONG Zijia, LI Jun, LI You, CAI Dongli, ZHAO Ren. Expression of B7S1 related with immune infiltration in colorectal cancer [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 336-342. |
[7] | WU Chunxiao, GONG Yangming, GU Kai, PANG Yi, BAO Pingping, WANG Chunfang, SHI Liang, XIANG Yongmei, DOU Jianming, FU Chen, SHI Yan. Colorectal cancer incidence and mortality in Shanghai 2016 and trend analysis 2002—2016 [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 325-335. |
[8] | MAO Jieqi, XU Duogang, ZHANG Mili, XIAO Yunyu, MING Xu, LI Yuzhe, CAO Can, YU Liang, LI Jikun. Study on D-dimer elevation in patients with colorectal cancer [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 361-366. |
[9] | LIN Songbin, FENG Qingyang, XU Jianmin. KRAS genotypes predict metachronous colorectal cancer distant metastases after radical resections [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 66-71. |
[10] | XU Chenying, XU Qingling, TANG Chenyue, YU Lifen. Detection rate of colorectal adenoma in the asymptomatic population of 40 to 59 years and its relationship with the detected gastric polyps in Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(05): 504-509. |
[11] | CUI Ang, DING Jiazeng, CHEN Haizhen, SHEN Xiaohui, LI Chaofei, LIU Guoliang. Downregulation of trimethyl transferase SETD2 promotes migration and proliferation of colorectal cancer cell [J]. Journal of Surgery Concepts & Practice, 2020, 25(02): 139-145. |
[12] | WANG Ziyuan, LIANG Tingyu, CHEN Jia, HAN Zhihong, WU Lili. Analysis of KRAS, NRAS and BRAF mutations in colorectal cancer and their correlation with clinicopathologic features and p53 protein expression [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(06): 687-693. |
[13] | JIANG Yimei, LIU Kun, SHI Yiqin, SONG Zijia, LI You, ZHAO Ren. Single-port and three-port laparoscopic radical resection in colorectal cancer: a retrospective study [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 418-424. |
[14] | LIU Kun, LUO Fangxiu, FANG Xuqian, SHI Yiqing, JIANG Yimei, CHEN Peizhan, ZHAO Ren. Relationship between Cortactin expression level and tumor budding in colorectal cancer [J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 425-429. |
[15] | ZHOU Yong, CUI Rong, SHI Xingyao. Analysis of long non-coding RNA TUG1 expression in colorectal cancer [J]. Journal of Surgery Concepts & Practice, 2018, 23(04): 374-378. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||